Japan and Singapore forge biomaterials deal:
This article was originally published in Clinica
The Japanese National Institute for Materials Science and the National University of Singapore last month signed memorandum to collaborate in the field of biomaterials research. Under the agreement, both sides will exchange information and share technology for the designing and processing of biomaterials. The aim is to commercialise new products for advanced medical treatment. The memorandum is part of the Japan-Singapore Economic Agreement, concluded in January 2002, contained within the New Age Partnership, which also includes a bilateral trade agreement, reports Japan Chemical Week.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.